A Mini-Review on Potential of Neuropeptides as Future Therapeutics

Sharma, Deepika; Kumar, Krishan; Bisht, Gopal Singh

doi:10.1007/s10989-021-10309-6

Cited by 5 publications

(2 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other neuropeptides such as oxytocin, ghrelin, dynorphin, orexin, etc also have diverse roles in the nervous system and may have different effects on seizure activity depending on the part of the brain it is affecting, the type of epilepsy, and the overall regulatory mechanism involving targeting receptors [16]. It is crucial to note that the relationship between neuropeptides and epilepsy is not easy to understand and is quite complicated.…”

Section: Role Of Neuropeptide Y In Epilepsymentioning

confidence: 99%

“…Neuropeptides, as compared to classical neurotransmitters, have longer half-lives and can exert their effects over prolonged periods. Neuropeptides, such as neuropeptide Y (NPY), substance P, galanin, and others, are released from specific neurons and can act as neuromodulators or co-transmitters [16]. Unlike fast-acting neurotransmitters, neuropeptides are typically released in larger quantities and have longer-lasting effects due to their slower degradation and clearance rate, neuronal excitability, and setting the seizure threshold [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnological advances in the treatment of epilepsy: a comprehensive review

Rai,

Sharma,

Bhasin

et al. 2024

Nanotechnology

View full text Add to dashboard Cite

Epilepsy is one of the most prevalent chronic neurological disorders characterized by frequent unprovoked epileptic seizures. Epileptic seizures can develop from a broad range of underlying abnormalities such as tumours, strokes, infections, traumatic brain injury, developmental abnormalities, autoimmune diseases, and genetic predispositions. Sometimes epilepsy is not easily diagnosed and treated due to the large diversity of symptoms. Undiagnosed and untreated seizures deteriorate over time, impair cognition, lead to injuries, and can sometimes result in death. This review gives details about epilepsy, its classification on the basis of ILAE, current therapeutics which are presently offered for the treatment of epilepsy. Despite of the fact that more than 30 different AED and antiseizure drugs are available, large number of epileptic patients fail to attain prolonged seizure independence. Poor onsite bioavailability of drugs due to Blood Brain Barrier poses a major challenge in drug delivery to brain. The present review covers the limitations with the state-of-the-art strategies for managing seizures and emphasizes the role of nanotechnology in overcoming these issues. Various nano-carriers like polymeric nanoparticles, dendrimers, lipidic nanoparticles such as solid lipid nanoparticles, nano-lipid carriers, have been explored for the delivery of anti-epileptic drugs to brain using oral and intranasal routes. Nano-carries protect the encapsulated drugs from degradation and provide a platform to deliver controlled release over prolonged periods, improved permeability and bioavailability at the site of action. The review also emphasises in details about the role of neuropeptides for the treatment of epilepsy.

show abstract

Section: Role Of Neuropeptide Y In Epilepsymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%